Health Catalyst (NASDAQ:HCAT) Issues Earnings Results

Health Catalyst (NASDAQ:HCAT) released its quarterly earnings results on Monday. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.01, FiscalAI reports. Health Catalyst had a negative return on equity of 4.30% and a negative net margin of 57.20%.The company had revenue of $70.76 million for the quarter, compared to analysts’ expectations of $69.24 million.

Here are the key takeaways from Health Catalyst’s conference call:

• Q1 results beat guidance with $70.8 million revenue, $9.1 million adjusted EBITDA, and cash/short-term investments of $108.8 million, signaling improved liquidity and cost discipline.
• Project Nexus is expected to deliver roughly $30 million of annualized run-rate savings (with ~9% headcount reduction) despite ~$4 million of near-term restructuring charges, aiming to improve margins and operating efficiency.
• The prior rigid DOS-to-Ignite migration strategy created churn; management now expects ~$20 million of migration-related revenue impact in 2026 (and ~$10 million in 2027) after assessing $52 million of at?risk ARR and retaining at least $22 million.
• Management is prioritizing an AI-led product strategy—“Ignite Intelligence” backed by 18 years of proprietary improvement data—and early engineering pilots (AI agents/pods) have materially increased developer productivity.
• The company reinstated full-year 2026 guidance: total revenue of $260–265 million and adjusted EBITDA of $30–33 million, plus expectations of $22–26 million in new bookings and mid?60s technology margins by year-end.

Health Catalyst Stock Down 9.2%

Shares of NASDAQ:HCAT opened at $1.38 on Tuesday. The firm’s 50 day moving average price is $1.36 and its 200 day moving average price is $2.06. The stock has a market cap of $101.55 million, a price-to-earnings ratio of -0.54 and a beta of 1.63. Health Catalyst has a fifty-two week low of $0.96 and a fifty-two week high of $4.74. The company has a quick ratio of 1.89, a current ratio of 1.89 and a debt-to-equity ratio of 0.62.

Institutional Trading of Health Catalyst

Several hedge funds have recently added to or reduced their stakes in the company. nVerses Capital LLC acquired a new position in shares of Health Catalyst in the 4th quarter valued at $25,000. Cresset Asset Management LLC acquired a new stake in shares of Health Catalyst in the 2nd quarter worth $39,000. Focus Partners Wealth purchased a new stake in shares of Health Catalyst in the first quarter valued at about $46,000. BNP Paribas Financial Markets boosted its holdings in shares of Health Catalyst by 71.7% in the third quarter. BNP Paribas Financial Markets now owns 16,355 shares of the company’s stock valued at $47,000 after acquiring an additional 6,832 shares in the last quarter. Finally, Quadrature Capital Ltd acquired a new position in Health Catalyst during the 4th quarter worth approximately $64,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst News Summary

Here are the key news stories impacting Health Catalyst this week:

• Positive Sentiment: Health Catalyst reported Q1 2026 EPS of $0.02, topping the $0.01 consensus estimate, and revenue of $70.76 million, also above expectations. The results suggest the business is still executing better than Wall Street expected. Health Catalyst Reports First Quarter 2026 Results
• Positive Sentiment: Several articles highlighted that the company’s Q1 sales beat estimates, which helped lift investor sentiment intraday. Health Catalyst’s (NASDAQ:HCAT) Q1 CY2026 sales beat estimates, stock jumps 11.1%
• Neutral Sentiment: Cantor Fitzgerald reaffirmed a neutral rating on Health Catalyst, which does not materially change the investment case but signals a wait-and-see stance. Health Catalyst (NASDAQ:HCAT) Receives Neutral Rating from Cantor Fitzgerald
• Neutral Sentiment: Investors also reviewed the Q1 earnings call transcript for more detail on management’s outlook and execution priorities. Health Catalyst, Inc. (HCAT) Q1 2026 Earnings Call Transcript
• Negative Sentiment: The company guided second-quarter revenue to $68.0 million-$70.0 million, below the $70.7 million consensus estimate, raising concern that growth may slow in the near term. Health Catalyst stock page / earnings report
• Negative Sentiment: Health Catalyst continues to show weak profitability metrics, including a negative net margin and negative return on equity, which can limit enthusiasm even after an earnings beat. Health Catalyst stock page / earnings report

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Citigroup decreased their price target on Health Catalyst from $2.75 to $1.75 and set a “neutral” rating on the stock in a research note on Friday, March 13th. Wells Fargo & Company reissued an “equal weight” rating and set a $1.00 price target (down from $5.00) on shares of Health Catalyst in a research report on Wednesday, March 18th. Stephens reduced their price target on shares of Health Catalyst from $3.50 to $2.00 and set an “equal weight” rating on the stock in a research report on Friday, March 13th. Raymond James Financial set a $3.00 price target on shares of Health Catalyst in a research report on Friday, March 13th. Finally, Stifel Nicolaus reduced their price target on shares of Health Catalyst from $3.75 to $2.00 and set a “hold” rating on the stock in a research report on Friday, March 13th. Four research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $2.80.

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.